Lorlatinib. a third-generation anaplastic lymphoma kinase (ALK)/receptor tyrosine kinase inhibitor (ROS1). demonstrated efficacy in ROS1 positive (ROS1+) non-small cell lung cancer (NSCLC). although approval is currently limited to the treatment of ALK+ patients. https://www.markbroyard.com/best-grab-sukin-hydrating-body-lotion-250ml-fashion-save-extra/